197
Views
8
CrossRef citations to date
0
Altmetric
Review

Vascular endothelial growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small cell lung cancer

, , &
Pages 491-506 | Received 07 Aug 2019, Accepted 06 Jan 2020, Published online: 20 Jan 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Jian-De Cheng, Li-Xun Chai, Zhi-Ping Zhao, Yan-Yan Hao & Shuo Li. (2020) Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor. Cancer Management and Research 12, pages 5641-5650.
Read now

Articles from other publishers (7)

Sudhir M. Hiremath & Seema S. Khemalapure. (2023) Synthesis, Spectroscopic (FT‐IR, FT‐Raman), Electronic Properties and Molecular Docking Studies of 1‐(2, 6‐dibromo‐4‐methyl‐phenoxymethyl)‐benzo[f]chromen‐3‐one. ChemistrySelect 8:25.
Crossref
Keqian Zhang, Wenwei Wang, Ting Zhang & Lan Liang. (2022) Efficacy and treatment-related adverse events of multi-targeted tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. International Journal of Clinical Pharmacy 44:6, pages 1232-1246.
Crossref
Anuruddha R. Chabukswar, Rajesh B. Nanaware, Swati Jagdale, Suraj B. Nanaware & Jaiprakash Sangshetti. (2022) Molecular Docking Studies and in silico ADMET Screening of Indazole Scaffolds as VEGFR and Enoyl-ACP (CoA) Reductase Inhibitors. Asian Journal of Chemistry 34:9, pages 2311-2317.
Crossref
Abdelsalam Mohamed Abdelsalam Ouf, Heba Abdelrasheed Allam, Marwa Kamel, Fatma A. Ragab & Salah A. Abdel-Aziz. (2022) Design, synthesis, cytotoxic and enzyme inhibitory activities of 1,3,4-oxadiazole and 1,3,4-thiadiazine hybrids against non-small cell lung cancer. Results in Chemistry 4, pages 100373.
Crossref
Wenjie Zhang, Chufeng Zhang, Shengjie Yang, Qing Chen, Chen Wang & Qisen Guo. (2021) Immune checkpoint inhibitors plus anlotinib versus anlotinib alone as third-line treatment in advanced non-small-cell lung cancer: a retrospective study. Future Oncology 17:31, pages 4091-4099.
Crossref
Yue Zhou, Mei He, Rui Li, Yuan Peng, Feng Li, Shengqian Li & Ming Yang. (2021) The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. BioMed Research International 2021, pages 1-10.
Crossref
Min-Huan Ren, Si Chen, Liang-Ge Wang, Wen-Xiu Rui & Pei Li. (2021) LINC00941 Promotes Progression of Non-Small Cell Lung Cancer by Sponging miR-877-3p to Regulate VEGFA Expression. Frontiers in Oncology 11.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.